Mobile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis

Update Il y a 4 ans
Reference: EUCTR2010-018385-23

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally twice per day [BID]), compared with placebo, on the signs and symptoms of psoriatic arthritis (PsA) after 24 weeks’ administration

Inclusion criteria

  • Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients

Links